16 June 2025 - AVEROA actively seeking strategic partners and investors to bring Xoanacyl to European patients and unlock full ...
16 June 2025 - FDA assigns PDUFA target action date of 31 January 2026 ...
13 June 2025 - Agency indicates anticipated decision within four weeks ...
16 June 2025 - The EMA has published a draft agenda for this week's CHMP meeting. ...
15 June 2025 - Approval of 45 mg/0.5 mL solution in a single-dose vial for subcutaneous injection expands dosing flexibility for ...
9 June 2025 - Pfizer and other drug companies have met with the Trump administration to discuss lowering US drug ...
12 June 2025 - Xediton Pharmaceuticals is proud to announce that Vabomere (meropenem-vaborbactam) has been approved by Health Canada and ...
13 June 2025 - Regulatory decision anticipated H1, 2026. ...
12 June 2025 - Expanded indication builds on existing US FDA approval of mRESVIA for adults aged 60 and older. ...
13 June 2025 - People in England will become the first in the world to receive belantamab mafodotin for this indication ...
11 June 2025 - AbbVie Korea's Epkinly (epcoritamab), a treatment for adults with relapsed or refractory diffuse large B-cell lymphoma ...
13 June 2025 - Belgium-based UCB's novel psoriasis therapy, Bimzelx (bimekizumab), has officially entered Korea's competitive plaque psoriasis market with ...
12 June 2025 - Innoviva Specialty Therapeutics today announced that the US FDA has granted priority review for the new drug ...
12 June 2025 - Nuvisertib (TP-3654), an investigational highly selective oral PIM1 kinase inhibitor, is being evaluated in patients with ...
12 June 2025 - Today, the FDA approved pembrolizumab (Keytruda, Merck) for adults with resectable locally advanced head and neck ...
12 June 2025 - Today, the FDA approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for adult patients with recurrent low-grade ...